SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 196 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 1.93 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $23,319 | -41.7% | 13,249 | +4.0% | 0.00% | -60.0% |
| Q4 2022 | $39,985 | +471.2% | 12,734 | +848.9% | 0.01% | +400.0% |
| Q3 2022 | $7,000 | -56.2% | 1,342 | -65.5% | 0.00% | -50.0% |
| Q2 2022 | $16,000 | +1500.0% | 3,892 | +2287.7% | 0.00% | – |
| Q1 2022 | $1,000 | – | 163 | +83.1% | 0.00% | – |
| Q1 2020 | $0 | – | 89 | +50.8% | 0.00% | – |
| Q4 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 59 | 0.0% | 0.00% | – |
| Q3 2018 | $1,000 | – | 59 | 0.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 59 | -88.5% | 0.00% | -100.0% |
| Q1 2018 | $9,000 | +12.5% | 514 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $8,000 | +14.3% | 514 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $7,000 | +75.0% | 514 | 0.0% | 0.00% | +50.0% |
| Q2 2017 | $4,000 | +100.0% | 514 | 0.0% | 0.00% | +100.0% |
| Q1 2017 | $2,000 | – | 514 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |